At the news
? NEUTRALIMPACT 3/10 PRESS-RELEASE filed Nov 3, 2026 at 07:00 ET
PTC Therapeutics announced a $500 million share repurchase program, representing ~9.3% of its $5.4B market cap. The buyback follows strong Q3 2026 results reported 5 days ago, where total revenue of $357.6M beat consensus and full-year product revenue guidance was raised to $960M-$990M.
- Board authorized up to $500 million in share repurchases
- Repurchases may be made through open-market transactions, privately negotiated deals, or accelerated share repurchases
- Authorization represents ~9.3% of current market cap ($5.4B)
- Follows Q3 2026 earnings beat (revenue $357.6M vs $305.0M consensus) and raised product revenue guidance to $960M-$990M
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access